[Capecitabine (Ro09-1978) for therapy of advanced and recurrent gastric cancer].
Koizumi
W
W
Department of Internal Medicine, School of Medicine, Kitasato University.
D000284:Administration, Oral; D000818:Animals; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D042943:Dihydrouracil Dehydrogenase (NADP); D015195:Drug Design; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D010088:Oxidoreductases / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013939:Thymidine Phosphorylase / Q000378:metabolism; D016896:Treatment Outcome
D003841:Deoxycytidine; D000069287:Capecitabine; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D013939:Thymidine Phosphorylase; D005472:Fluorouracil